FDA agrees to deal that speeds reviews

Share this article:
The Food and Drug Administration and the biopharma industry have agreed in principle on a revamp of the Prescription Drug User Fee Act, by which drug firms provide nearly two-thirds of what the agency spends on drug reviews.

The agency, which is still wrangling with the generic drug and device industries over user fee agreements, published a draft, dubbed “PDUFA Reauthorization Performance Goals for 2013 through 2017,” which the Pharmaceutical Research and Manufacturers of America described as “the result of lengthy technical negotiations between the biopharmaceutical industry and the FDA.”

The act was first enacted in 1992.The agency's new outline includes measures aimed at speeding reviews of New Molecular Entities, in part by facilitating more and better dialogue between companies with NMEs up for review and the agency. That had emerged as a priority during the drafting of industry's PDUFA wish list.

Biotech trade group BIO gave the agreement its blessing, expressing hopes of improved communication and less unpredictability for stakeholders.

The agreement must be voted on by Congress and signed by the president before September 2012, when the current PDUFA expires, or the approvals process could grind to a near halt.
Share this article:
close

Next Article in News

More in News

Bulk of Medicaid to be managed care in two years: Avalere

Bulk of Medicaid to be managed care in ...

More than three-quarters of Medicaid beneficiaries will be enrolled in a managed care plan as of 2016, according to an Avalere Health analysis released Thursday. The numbers reveal that managed ...

Nursing home asked for employee's personal information too often, jury rules

The human resources department of a Maine nursing home did not properly protect a former employee's personal identification information, a jury recently ruled.

Test could confirm sepsis within an hour

Nursing home residents might benefit from a new way of diagnosing and treating sepsis made possible by discoveries out of the University of British Columbia.